Prevention and treatment of recurrent fractures after percutaneous vertebroplasty with denosumab in patients with osteoporotic vertebral compression fractures

[Objective] To investigate the preventive effect of denosumab on recurrent fractures after percutaneous vertebroplasty in patients with osteoporotic vertebral compression fractures. [Methods] A total of 72 patients diagnosed with osteoporotic vertebral compression fracture and treated by percutaneou...

Full description

Saved in:
Bibliographic Details
Main Authors: Shouyu Xiang, Cheng Tang, Long Ling, Wei Liu, Bingwen Bai, Yanming Cao
Format: Article
Language:zho
Published: Editorial Office of International Journal of Geriatrics 2025-01-01
Series:Guoji laonian yixue zazhi
Subjects:
Online Access:http://gwll.publish.founderss.cn/thesisDetails#10.3969/j.issn.1674-7593.2025.01.004&lang=en
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832592773792923648
author Shouyu Xiang
Cheng Tang
Long Ling
Wei Liu
Bingwen Bai
Yanming Cao
author_facet Shouyu Xiang
Cheng Tang
Long Ling
Wei Liu
Bingwen Bai
Yanming Cao
author_sort Shouyu Xiang
collection DOAJ
description [Objective] To investigate the preventive effect of denosumab on recurrent fractures after percutaneous vertebroplasty in patients with osteoporotic vertebral compression fractures. [Methods] A total of 72 patients diagnosed with osteoporotic vertebral compression fracture and treated by percutaneous vertebroplasty in the orthopedic department of the Second Affiliated Hospital of Guangzhou Medical University from January 2022 to December 2022 were selected as the study subjects.Patients were randomly divided into two groups, each had 36 cases.The control group received conventional anti-osteoporosis treatment, and the observation group added denosumab on the basis of control group treatment.Both groups were followed for 1 year, while the fracture rate and the levels of bone mineral density(BMD), visual analogue scale(VAS) score, oswestry disability index(ODI), beck value, sagittal cobb angle and procollagen type ⅠN-terminal propeptid(PINP) and β-carboxy-terminal cross-linked telopeptide of type Ⅰ collagen(β-CTX) were compared between the two groups. [Results] There was no significant preoperative on BMD, VAS score, ODI index,beck values, sagittal cobb angle, PINP and β-CTX levels between the two groups before the surgery(P>0.05); After postoperative follow-up of 6 months, BMD in the observation group was higher than that in the control group (P<0.05), while VAS score, ODI index, PINP and β-CTX levels were lower than those in the control group (P<0.05).At 1 year postoperative follow-up, BMD and beck values in the observation group were higher than those in the control group (P<0.05), while fracture rate, VAS score, ODI index, sagittal cobb angle and PINP and β-CTX levels were lower than those in the control group(P<0.05). [Conclusion] Denosumab treatment effectively relieves pain after percutaneous vertebroplasty in patients with osteoporotic vertebral compression fractures, promotes fracture healing, increases vertebral bone mineral density, and reduces the incidence of vertebral refractures.
format Article
id doaj-art-20d37dd79bef4316a916012fc65d88f0
institution Kabale University
issn 1674-7593
language zho
publishDate 2025-01-01
publisher Editorial Office of International Journal of Geriatrics
record_format Article
series Guoji laonian yixue zazhi
spelling doaj-art-20d37dd79bef4316a916012fc65d88f02025-01-21T02:59:39ZzhoEditorial Office of International Journal of GeriatricsGuoji laonian yixue zazhi1674-75932025-01-01461161910.3969/j.issn.1674-7593.2025.01.004Prevention and treatment of recurrent fractures after percutaneous vertebroplasty with denosumab in patients with osteoporotic vertebral compression fracturesShouyu Xiang0Cheng Tang1Long Ling2Wei Liu3Bingwen Bai4Yanming Cao5Department of Orthopedics, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510245Department of Orthopedics, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510245Department of Orthopedics, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510245Department of Orthopedics, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510245Department of Orthopedics, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510245Department of Orthopedics, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510245[Objective] To investigate the preventive effect of denosumab on recurrent fractures after percutaneous vertebroplasty in patients with osteoporotic vertebral compression fractures. [Methods] A total of 72 patients diagnosed with osteoporotic vertebral compression fracture and treated by percutaneous vertebroplasty in the orthopedic department of the Second Affiliated Hospital of Guangzhou Medical University from January 2022 to December 2022 were selected as the study subjects.Patients were randomly divided into two groups, each had 36 cases.The control group received conventional anti-osteoporosis treatment, and the observation group added denosumab on the basis of control group treatment.Both groups were followed for 1 year, while the fracture rate and the levels of bone mineral density(BMD), visual analogue scale(VAS) score, oswestry disability index(ODI), beck value, sagittal cobb angle and procollagen type ⅠN-terminal propeptid(PINP) and β-carboxy-terminal cross-linked telopeptide of type Ⅰ collagen(β-CTX) were compared between the two groups. [Results] There was no significant preoperative on BMD, VAS score, ODI index,beck values, sagittal cobb angle, PINP and β-CTX levels between the two groups before the surgery(P>0.05); After postoperative follow-up of 6 months, BMD in the observation group was higher than that in the control group (P<0.05), while VAS score, ODI index, PINP and β-CTX levels were lower than those in the control group (P<0.05).At 1 year postoperative follow-up, BMD and beck values in the observation group were higher than those in the control group (P<0.05), while fracture rate, VAS score, ODI index, sagittal cobb angle and PINP and β-CTX levels were lower than those in the control group(P<0.05). [Conclusion] Denosumab treatment effectively relieves pain after percutaneous vertebroplasty in patients with osteoporotic vertebral compression fractures, promotes fracture healing, increases vertebral bone mineral density, and reduces the incidence of vertebral refractures.http://gwll.publish.founderss.cn/thesisDetails#10.3969/j.issn.1674-7593.2025.01.004&lang=endenosumabosteoporotic vertebral compression fracturesvertebroplasty
spellingShingle Shouyu Xiang
Cheng Tang
Long Ling
Wei Liu
Bingwen Bai
Yanming Cao
Prevention and treatment of recurrent fractures after percutaneous vertebroplasty with denosumab in patients with osteoporotic vertebral compression fractures
Guoji laonian yixue zazhi
denosumab
osteoporotic vertebral compression fractures
vertebroplasty
title Prevention and treatment of recurrent fractures after percutaneous vertebroplasty with denosumab in patients with osteoporotic vertebral compression fractures
title_full Prevention and treatment of recurrent fractures after percutaneous vertebroplasty with denosumab in patients with osteoporotic vertebral compression fractures
title_fullStr Prevention and treatment of recurrent fractures after percutaneous vertebroplasty with denosumab in patients with osteoporotic vertebral compression fractures
title_full_unstemmed Prevention and treatment of recurrent fractures after percutaneous vertebroplasty with denosumab in patients with osteoporotic vertebral compression fractures
title_short Prevention and treatment of recurrent fractures after percutaneous vertebroplasty with denosumab in patients with osteoporotic vertebral compression fractures
title_sort prevention and treatment of recurrent fractures after percutaneous vertebroplasty with denosumab in patients with osteoporotic vertebral compression fractures
topic denosumab
osteoporotic vertebral compression fractures
vertebroplasty
url http://gwll.publish.founderss.cn/thesisDetails#10.3969/j.issn.1674-7593.2025.01.004&lang=en
work_keys_str_mv AT shouyuxiang preventionandtreatmentofrecurrentfracturesafterpercutaneousvertebroplastywithdenosumabinpatientswithosteoporoticvertebralcompressionfractures
AT chengtang preventionandtreatmentofrecurrentfracturesafterpercutaneousvertebroplastywithdenosumabinpatientswithosteoporoticvertebralcompressionfractures
AT longling preventionandtreatmentofrecurrentfracturesafterpercutaneousvertebroplastywithdenosumabinpatientswithosteoporoticvertebralcompressionfractures
AT weiliu preventionandtreatmentofrecurrentfracturesafterpercutaneousvertebroplastywithdenosumabinpatientswithosteoporoticvertebralcompressionfractures
AT bingwenbai preventionandtreatmentofrecurrentfracturesafterpercutaneousvertebroplastywithdenosumabinpatientswithosteoporoticvertebralcompressionfractures
AT yanmingcao preventionandtreatmentofrecurrentfracturesafterpercutaneousvertebroplastywithdenosumabinpatientswithosteoporoticvertebralcompressionfractures